Loading...
•
Dec 31, 2024
Nature's Sunshine Q4 2024 Earnings Report
Estimated Revenue:$112M
+2.5% YoY
Estimated EPS:$0.205
+39.6% YoY
Key Takeaways
Nature's Sunshine experienced strong revenue growth of 8.5% in Q4 2024, driven by double-digit gains in the Asia segment. However, rising selling, general, and administrative (SG&A) expenses and foreign exchange losses led to a net loss of $0.3 million. Adjusted EBITDA grew by 6% to $10.3 million, reflecting continued operational efficiency improvements.
Revenue increased 8.5% year-over-year to $118.2 million, with 17.7% growth in Asia.
Gross margin improved slightly to 72.0%, compared to 71.9% in Q4 2023.
Net loss was $0.3 million, compared to net income of $9.0 million in Q4 2023.
Adjusted EBITDA increased 6% to $10.3 million, highlighting cost-saving initiatives.
Nature's Sunshine
Nature's Sunshine
Nature's Sunshine Revenue by Geographic Location
Revenue by Geographic Location
Asia Revenue
CapyFin.comEurope Revenue
CapyFin.comNorth America Revenue
CapyFin.comLatin America and Other Revenue
CapyFin.com Forward Guidance
Nature's Sunshine expects continued revenue growth in 2025, driven by strong performance in Asia and Europe. The company remains focused on cost-saving initiatives to improve profitability, despite macroeconomic challenges.
Positive Outlook
- Revenue growth in Asia expected to continue in 2025.
- Cost-saving initiatives are positively impacting profitability.
- Strong cash position of $84.7 million supports strategic investments.
- Digital sales in North America grew 17% in Q4 2024, signaling a shift towards e-commerce.
- Operational efficiencies and pricing adjustments are expected to offset inflationary pressures.
Challenges Ahead
- Increased SG&A expenses are impacting net profitability.
- Foreign exchange losses negatively affected earnings in Q4 2024.
- Macroeconomic uncertainty may impact consumer spending in key markets.
- North America sales declined by 1.6% year-over-year.
- Continued inflationary pressures may affect gross margins in future quarters.
Loading...
Key Statistics
Market Cap
$297M
P/E Ratio
21.03
Sector
Health Technology
Industry
Pharmaceuticals Other
52-Week High
$17.3
52-Week Low
$11.3
Gross Profit Margin
72%
SG&A Expenses % of Sales
37%
Adjusted EBITDA
$10.3M